Apple, you see, isn’t simply selling devices. It’s cultivated an ecosystem, a connected world where one purchase tends another. It’s a modern take on the family farm, where loyalty isn’t bought with discounts, but grown from a shared experience. The iPhone 17, a smooth stone in the hand, has moved well, driven by those willing to pay a little more for the tools that matter. They say supply constrained the numbers. That’s often the case when something is truly wanted.
Yet, 2026… this year holds a certain weight, a possibility. If the currents align, if the winds of circumstance favor the vessel, then perhaps that elusive number might finally be breached. But the ocean is vast, and the storms are unpredictable. Let us consider, then, what must occur for this coin to double in value, to finally claim its place among the higher orders of digital worth.
Wegovy and Zepbound, those names sound like villains in a low-budget sci-fi film, have been doing quite well, thank you. Top ten best-selling drugs. It’s a little unsettling, isn’t it? The casual commodification of desperation. Anyway, two companies, Amgen (AMGN +0.66%) and Roche (OTC: RHHB.Y), are poised to enter this lucrative, and frankly, slightly depressing market. The question isn’t necessarily whether these drugs work – they seem to, at least temporarily – but whether the stocks are worth a look. I’ve been staring at the charts, trying to decipher the meaning, and mostly I just feel tired.
The quarterly earnings, as reported, were…adequate. A surplus of profit, exceeding expectations, as is so often the case. The numbers themselves – $7.54 per share on sales of $19.3 billion – are merely figures, after all. They tell little of the hopes pinned upon these earnings, the quiet ambition that drives the laboratories, the countless hours dedicated to a market hungry for solutions. The forecast for 2026 is optimistic, predicting between $33.50 and $35 per share. One wonders if optimism is always a virtue.
Investors, it seemed, were picking up pieces after a bruising 2025, a year where Fluor shares lost nearly a fifth of their value. A growing order book, a promise of work to be done, offered a flicker of hope. The full accounting will come on February 17th, when Fluor reveals its fourth-quarter results, but the scent of potential is in the air.
Crypto Patel, a name that echoes through the halls of Twitter with the gravitas of a fortune-teller at a provincial fair, declared on the fourth of February that XRP/USD had “graced its first accumulation zone at $1.50-$1.30.” With the air of a man dispensing wisdom to the uninitiated, he urged his followers to adopt a strategy of staggered entries, as if timing the market were a folly reserved for the unwashed masses. “Accumulate steadily,” he intoned, “for in this lies the preservation of capital.” A noble sentiment, though one wonders if his earlier proclamations were equally prescient.
The market, as these things will, reacted with a certain enthusiasm. The stock price, I am informed, performed a bit of a jig on Tuesday, leaping upwards before settling back to a more reasonable pace. As we speak, it’s still showing a most respectable advance. One can’t help but feel a tiny bit pleased for the chaps involved.
Giancarlo’s yapping about regulatory clarity like it’s the cure for baldness. Apparently, without it, American banks are gonna end up like Blockbuster in a Netflix world. Yikes. Meanwhile, Europe’s over there sipping espresso and using XRP like it’s no big deal. Thanks, MiCA, for not being a total buzzkill.
Dominion Energy [D +0.50%] presents itself as a rather sensible proposition. Not a rocket ship to Mars, mind you, but a sturdy barge, reliably transporting wealth. A dividend yield of 4.4% is hardly a revolutionary concept, but in an age of vaporware and promises, it feels remarkably…substantial.
Right now, a big chunk of CoreWeave’s money comes from a few very large artificial intelligence labs. Not a flaw, exactly. In the beginning, those were the only ones who needed that much computing power. CoreWeave was quick. They gave the labs what they wanted. It was inevitable. Like taxes and death.